📢 Join us tomorrow for a special @TumorBoardTuesday coming 🔥🔥 from MIAMI☀️ 🌴 to discuss #EGFREx20ins 🎯 lung cancer with Chinmay Jani @latinamd
📅Tues 05/21/2024 at 8pm ET

RT and bring others to the discussion‼️
#lcsm Exon 20 Group, a multi-stakeholder organization

“Did you hear?! #ASCO24 has THREE lung cancer trials at the Plenary!!”

Bruna Pellini, MD ASCO #lcsm 🤣

Thanks Irish Cancer Society for including a familiar face in their new TV ad!

Thanks to this dynamic society for funding my research & others. Your support has led to real progress for patients

Beaumont RCSI Cancer Centre RCSI Research and Innovation Beaumont Hospital #IrishLungCancerAlliance #IrishLungCancerCommunity #LCSM

Stepping up for #lunghealth and #lungcancer this morning with the American Lung Association’s Texas Two-Step!

Honored to lead our MD Anderson Cancer Center team! #lcsm #EndCancer 🏃🏽‍♂️🫁

Fantastic news for our ALK+ #lungcancer community 🙌

The U.S. FDA has granted breakthrough therapy designation to Nuvalent's NVL-655 for the treatment of patients with locally advanced or metastatic ALK+ LC who have been previously treated 2+ TKIs.

#LCSM #ResearchSavesLives

Step up for lung health & join me for the American Lung Association's Texas Two-Step event! 🤠🏃🏽‍♂️

📆 Saturday, May 18th
⏰ 8:00 AM
📍Rice University Stadium

Excited to be the physician lead for our MD Anderson Cancer Center team! 💪🏽 #EndCancer #lcsm

Sign up here: action.lung.org/site/TR/Climb/…

Looking for get involved in #Cancersupport advocacy? We're speaking about lung cancer but convo applicable to all. Join us for this live and lively discussion of advocacy across continents. IASLC ASCO, thnx Yvonne Diaz for hosting.

🫁 FLAURA 2 & MARIPOSA 🫁

🌟 Nice review & commnentary
Eric K. Singhi, MD & Balazs Halmos

💫 “Patients don’t want to just survive with stage IV lung
cancer; they want to live.” 💫
Jill Feldman , EGFR Resisters

Much impressive.

ASCO Daily News
#LCSM

High-yield IASLC Academy session this morning 🔥

🔸ACCE(ing) your presentations Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation
🔹Publish or Perish Christian Rolfo

Grateful to the co-chairs & faculty who are volunteering their time and expertise! #lcsm

Thank you Eric K. Singhi, MD Balazs Halmos for always bringing it back to the patient in clinic with you, for that’s what it’s all about! Shared decision making is 🔑 #patientadvocate

Christine Lovly, MD, PhD Eric K. Singhi, MD Balazs Halmos ASCO OncoAlert MD Anderson Cancer Center EGFR Resisters EGFR Positive UK ASCOPost Conquer Cancer, the ASCO Foundation Jill Feldman LungCancerRx 🫁💊 👏👏👏 phenomenal work Eric K. Singhi, MD and Balazs Halmos on this piece/practical analysis of the available data. Hopefully we will see updated data on #MARIPOSA (high risk patients) at #ASCO24 ! A poll we did to understand sequencing shortly after ESMO data last year 👇! But it will

With FLAURAishing new frontline combination therapies for EGFR+ mNSCLC yet incomplete data—What to do NOW in clinic? 🆘

Balazs Halmos & I share our thoughts for #ASCODailyNews 👇🏽

dailynews.ascopubs.org/do/deciding-be…

ASCO OncoAlert #lcsm

Like what you did there Eric K. Singhi, MD 🤩 Kudos for shedding light on the new treatment combos. Our landscape is FLAURAishing 🌸🫁 but navigating missing data and making informed clinical decisions are crucial for better outcomes for #EGFR + #NSCLC patients. #LungCancer #lcsm

Eric- btw- great timing on getting our The ASCO Post ASCO Daily News piece out on the FLAURA2/MARIPOSA data today! Eric K. Singhi, MD

I have been Singhing this Eric guy’s praise for a while- read this and you will see why!😉

With FLAURAishing new frontline combination therapies for EGFR+ mNSCLC yet incomplete data—What to do NOW in clinic? 🆘

Balazs Halmos & I share our thoughts for #ASCODailyNews 👇🏽

dailynews.ascopubs.org/do/deciding-be…

ASCO OncoAlert #lcsm

🍎 Garassino comments Cascone 🍎 and will be forever friends!♥️♥️♥️

Dr. Marina Garassino with a concise and balanced editorial NEJM on CheckMate 77T and the perioperative immunotherapy approach for resectable NSCLC. Impressive results, but who benefits from the adjuvant portion specifically?

nejm.org/doi/full/10.10…

🔥Hot off the press in NEJM

#CM77T Perioperative Nivolumab in Resectable NSCLC

▪️EFS HR 0.58
▪️pCR 25% (v ~5% chemo alone)

Another emerging perioperative option for our patients with stage IIA-IIIB NSCLC #lcsm OncoAlert

👉🏽 nejm.org/doi/full/10.10…

CM77T NEJM by Drs. Cascone M.Provencio Perioperative (chemo-nivo followed by adjuvant nivo) vs. neoadj chemo alone. Key image below, early days but new landmark analysis shows potential benefit from the adjuvant component for pts who have definitive surgery? #lcsm IASLC